Project Grant R41AI188982
Award Date 9/23/25
Completion Date 8/31/27
Dollars Obligated $282K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $299,644 to L2 Diagnostics LLC to develop a transmission-blocking vaccine (TBV) candidate that targets novel mosquito metabolic pathways to disrupt the transmission cycle of malaria. The goal is to create a vaccine that can be used alongside existing malaria vaccines to help eradicate the disease in...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, has awarded a $720,588 Project Grant to the Regents of the University of Minnesota. The grant supports the "Development of Broadly Protective Vaccines Against New World Arenaviruses" project, which aims to leverage the Pichinde virus vaccine vector to develop safe and effective vaccines against pathogenic New World arenaviruses, such as the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $466,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to New York University School of Medicine. The grant will support research to elucidate the molecular process of orthopox virus entry, including the MPXV and VACV viruses, through a comparative analysis using methods from virology, proteomics, and immunology. The research aims to identify and characterize the interactions...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
- This $2,494,866 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize innate immune signaling pathways in the tick Ixodes scapularis. The project aims to improve understanding of immune signaling in ticks, which are vectors of Lyme disease and other emerging infectious diseases. The research will combine cell culture-based methods with in vivo assays...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $437,477 to New York University (NYU) to develop a human lymph node-on-a-chip microphysiological system for evaluating the effectiveness of vaccines against infectious diseases. The goal is to create a reliable in vitro model of human lymph nodes that can accurately replicate the immune response process and dynamics,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $207,262 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in Saint Louis to develop an mRNA vaccine against Bourbon virus, an emerging tick-borne pathogen. The primary objective is to evaluate the efficacy of the mRNA vaccine in a mouse model and determine its mechanism of action. A secondary objective is to test different viral antigens and...
- This federal Project Grant award, valued at $449,625.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to determine the morphology of the Lloviu virus (LLOV) virions and compare their structures to those of Ebola virus (EBOV) and Marburg virus (MARV). The research team will utilize cryogenic electron microscopy and tomography techniques to generate...
- This federal Project Grant award of $299,954 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of L2 Diagnostics LLC's novel malaria vaccine candidate called PFAG. The project aims to (i) optimize the PFAG vaccine construct and (ii) conduct efficacy testing to confirm the optimal design. PFAG is a multivalent peptide vaccine composed of synthetic peptides representing...